GlaxoSmithKline has jumped onto the T-cell cancer therapy bandwagon, taking an option with US biotech Adaptimmune to develop a treatment targeting a peptide found on the surface of most can
Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
Joe Jimenez is to step down after eight years as Novartis chief executive, and will be leaving on a high after last week’s first-in-class CAR-T approval.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
